Global Klebsiella Infection Market, By Treatment (Moxifloxacin, Ofloxacin, Levofloxacin, Ceftriaxone), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
Klebsiella Infection Market Analysis and Size
The global Klebsiella infection market is expected to witness significant growth during the forecast period. Rising prevalence of Klebsiella infections worldwide and emerging markets are the factors responsible for the growth of this market. The market is on the rise due to increase in the treatment procedures, R&D activities funded by government and rise in the population in this region. Klebsiellae account for almost 8% of all hospital-acquired infections. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global Klebsiella infection market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Klebsiella infections are mostly hospital acquired and patients who have weak immune system are more prone to these infections. Patients with a weak immune system or the ones who have an implanted medical device are at higher risk for Klebsiella infections. Wide use of antibiotics has resulted in the development of antibiotic-resistant strains of Klebsiella.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Moxifloxacin, Ofloxacin, Levofloxacin, Ceftriaxone), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Procarta Biosystems (U.K.), La Jolla Pharmaceutical Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Merck KGaA (Germany), Beckman Coulter Inc. (U.S.), bioMerieux (France), Bio-Rad Laboratories, Inc (U.S.), Quidel Corporation (U.S.), Eiken Chemical Co., Ltd. (Japan), Melinta Therapeutics LLC (U.S.), Northern Antibiotics Ltd (Finland), Sumitomo Pharma Co., Ltd. (Japan)
|
|
Market Opportunities
|
|
Global Klebsiella Infection Market Dynamics
Drivers
- Increased Demands of Diagnostic Tests
Different kinds of diagnostic procedures are helping to create opportunities of the global Klebsiella infection market. Tests such as laboratory tests, ultrasound, X-rays and many such other tests are available today with regards to this. All these factors are also contributing in the growth of the market
- Increase in the number of research and development activities
The market's growth is fueled by increase in the number of R&D activities. This will provide beneficial advantages for the global Klebsiella infection market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives. For instance, Tetraphase Pharmaceuticals, Inc. was funded with USD 67 million for the development of its pipeline drug TP-434. This is a potent antibiotic effective against multi drug resistant (MDR) gram negative microorganism and can aid in providing effective treatment in Klebsiella infection.
Opportunities
- Availability of Advanced Treatment Procedures
With each passing decade, varied treatment methods are being available that would help the patients' faster recovery. Treatment advancements in terms of new antibiotics are on the rise. Thus, it creates many opportunities in the market growth.
- Increasing Demand for Retail Pharmacies
The rise in the number of perinatal infections therapeutics being delivered through the retail pharmacies and the rising number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global Klebsiella infection market over a forecast period.
- High Cost
The huge expenditure associated with Klebsiella infections medications surely hamper the market growth.
This global Klebsiella infection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Klebsiella infection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Klebsiella infection Market Scope
The global Klebsiella infection market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Moxifloxacin
- Ofloxacin
- Levofloxacin
- Ceftriaxone
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Klebsiella Infection Market Regional Analysis/Insights
The global Klebsiella infection market is analysed and market size insights and trends are provided by treatmnet, distribution channel and end-user as referenced above.
The major countries covered in the global Klebsiella infection market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global Klebsiella infection market throughout the forecasted period due to rising prevalence of the infection
Asia-Pacific dominates the market due to increased WHO & government awareness programs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Klebsiella Infection Market Share Analysis
The global Klebsiella infection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global Klebsiella infection market
Key players operating in the global Klebsiella infection market include:
- Procarta Biosystems (U.K.)
- La Jolla Pharmaceutical Company (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Pfizer Inc. (U.S.), Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Bristol-Myers Squibb Company (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- Merck KGaA (Germany)
- Beckman Coulter Inc. (U.S.)
- bioMerieux (France)
- Bio-Rad Laboratories, Inc (U.S.)
- Quidel Corporation (U.S.)
- Eiken Chemical Co., Ltd. (Japan)
- Melinta Therapeutics LLC (U.S.)
- Northern Antibiotics Ltd (Finland)
- Sumitomo Pharma Co., Ltd. (Japan)
SKU-